Steroids and azathioprine in the treatment of IgA nephropathy

Clinical and Experimental Nephrology

Volumn 15, Issue 3, 2011, Pages 373-380

  Stangou, Maria ^a   Ekonomidou, Domniki ^a   Giamalis, Panagiotis ^a   Liakou, Helen ^a   Tsiantoulas, Apostolis ^a   Pantzaki, Afroditi ^b   Papagianni, Aikaterini ^a   Efstratiadis, George ^a   Alexopoulos, Efstathios ^a   Memmos, Dimitrios ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Aristotle University Medical School   (Greece)

Author keywords

Azathioprine; IgAN; Proteinuria; Steroids; Treatment

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCOSAHEXAENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID; METHYLPREDNISOLONE; POLYUNSATURATED FATTY ACID; PREDNISOLONE;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HEMATURIA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; KIDNEY FIBROSIS; KIDNEY FUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MESANGIUM CELL; MUSCLE WEAKNESS; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; REMISSION; RESPIRATORY TRACT INFECTION; SYSTOLIC BLOOD PRESSURE;

ADULT; AZATHIOPRINE; FATTY ACIDS, UNSATURATED; FEMALE; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, IGA; HUMANS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; RENIN-ANGIOTENSIN SYSTEM;

EID: 79959282580     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-011-0415-3     Document Type: Article

References (27)

1. Berthoux FC, Mohey H, Afiani A. Natural history of primary IgA nephropathy. Semin Nephrol. 2008;28:4-9.
2. Glassock RJ. IgA nephropathy: challenges and opportunities. Cleve Clin J Med. 2008;75:569-76.
3. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Roberts IS, Cook HT, Troyanov S et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009;76:546-56.
4. Alexopoulos E. Treatment of primary IgA nephrophty. Kidney Int. 2004;64:341-56.
5. Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004;5:157-63. (Pubitemid 38020707)
6. Manno C, Torres DD, Rossini M, Pesce F, Schena FP. Randomized controlled clinical trial of corticosteroids plus ACEinhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant. 2009;24:3694-701.
7. Shoji T, Nakanishi I, Suzuki A, et al. Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy. Am J Kidney Dis. 2000;35:194-201. (Pubitemid 30070839)
8. Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol. 2002;13:142-8. (Pubitemid 34042021)
9. Bantis C, Stangou M, Schlaugat C, Alexopoulos E, Pantzaki A, Memmos D, Ivens K, Heering PJ. Is presence of ANCA in crescentic IgA nephropathy a coincidence or novel clinical entity? A case series. Am J Kidney Dis. 2010;55(2):259-68.
10. Harmankaya O, Oztürk Y, Baştürk T, Obek A, Kiliçarslan I. Efficacy of immunosuppressive therapy in IgA nephropathy presenting with isolated hematuria. Int Urol Nephrol. 2002;33:167-71. (Pubitemid 34575432)
11. Yoshikawa N, Honda M, Iijima K, Awazu M, Hattori S, Nakanishi K, Ito H, Japanese Pediatric IgA Nephropathy Treatment Study Group. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol. 2006;1:511-7.
12. Pozzi C, Andrulli S, Pani A, Scaini P, Del Vecchio L, Fogazzi G, Vogt B, De Cristofaro V, Allegri L, Cirami L, Procaccini AD, Locatelli F. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol. 2010;21:1783-90.
13. Locatelli F, Pozzi C, Andrulli S. IgA nephritis: ACE inhibitors, steroids, both or neither? Nephrol Dial Transplant. 2006;21: 3357-61.
14. Praga M, Gutiérrez E, González E, Morales E, Hernández E. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol. 2003;14:1578-83. (Pubitemid 36687059)
15. Egido J. Vasoactive hormones and renal sclerosis. Kidney Int. 1996;49:578-97. (Pubitemid 26051838)
16. Alexopoulos E, Stangou M, Pantzaki A, Kirmizis D, Memmos D. Treatment of severe IgA nephropathy with omega-3 fatty acids: the effect of a "very low dose" regimen. Ren Fail. 2004;26:453-9.
17. Novak J, Tomana M, Matousovic K, et al. IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int. 2005;67:504-13. (Pubitemid 40139842)
18. Goumenos DS, Brown CB, Shortland J, el Nahas AM. Myofibroblasts, predictors of progression of mesangial IgA nephropathy? Nephrol Dial Transplant. 1994;9:1418-25.
19. Stangou M, Alexopoulos E, Papagianni A, et al. Urinary levels of epidermal growth factor, interleukin-6 and monocyte chemoattractant protein-1 may act as predictor markers of renal function outcome in immunoglobulin A nephropathy. Nephrology. 2009;14:613-20.
20. Stangou M, Alexopoulos E, Pantzaki A, Leonstini M, Memmos D. C5b-9 glomerular deposition and tubular alpha3beta1-integrin expression are implicated in the development of chronic lesions and predict renal function outcome in immunoglobulin A nephropathy. Scand J Urol Nephrol. 2008;42:373-80.
21. Goumenos D, Ahuja M, Shortland JR, Brown CB. Can immunosuppressive drugs slow the progression of IgA nephropathy? Nephrol Dial Transplant. 1995;10:1173-81.
22. Goumenos DS, Davlouros P, El Nahas AM, et al. Prednisolone and azathioprine in IgA nephropathy: a ten-year follow-up study. Nephron Clin Pract. 2003;93:58-68.
23. Maes BD, Oyen R, Claes K, et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int. 2004;65:1842-9. (Pubitemid 38591034)
24. Tang S, Leung JC, Chan LY, et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int. 2005;68:802-12. (Pubitemid 43323137)
25. Tang SC, Tang AW, Wong SS, Leung JC, Ho YW, Lai KN. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int. 2010;77(6):543-9.
26. Frisch G, Lin J, Rosenstock J, et al. Mycophenolate mofetil (MMF) vs. placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant. 2005;20:2139-45. (Pubitemid 41510089)
27. Chen X, Chen P, Cai G, et al. A randomized control trial of mycophenolate mofeil treatment in severe IgA nephropathy. Zhonghua Yi Xue Za Zhi. 2002;82:796-801.